34 completed, 10 terminated, 4 unknown, 2 active not recruiting. 35 Phase 2, 23 Phase 1, 3 Not applicable, 2 Early Phase 1, 1 Phase 3.
Follow montanide ISA 51: new trials by email Literature Review of montanide ISA 51 trials Research Report on montanide ISA 51
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas Biospecimen Collection, Computed Tomography, Incomplete Freund''s Adjuvant - Digestive System Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm | Phase 2 | Not yet recruiting | Roswell Park Cancer Institute | 60 | 2026-12-15 | 2026-10-20 |
| Testing the SurVaxM Vaccine for Lung Cancer Prevention Biospecimen Collection, Montanide ISA 51 VG, Questionnaire Administration - Lung Carcinoma | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 80 | 2026-10-01 | 2026-08-26 |
| KLH Challenge to Explore the Human Immune Response Keyhole-Limpet Hemocyanin, Saline, Montanide ISA 51 VG - Immune Response | Not applicable | Unknown | University of Oxford | 39 | 2023-03-01 | 2023-05-25 |
| TEIPP Immunotherapy in Patients With NSCLC TEIPP24 (LRPAP7-30V-SLP vaccine in Montanide ISA-51) - Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Erasmus Medical Center | 26 | 2021-09-29 | 2024-11-07 |
| The P10s-PADRE Basket Trial: Vaccination of Metastatic Cancer Patients P10s-PADRE - Neoplasms by Site, Metastatic Cancer | Phase 2 | Withdrawn | University of Arkansas | 2021-03-01 | 2024-09-03 | |
| Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence Pembrolizumab, SurVaxM, Sargramostim - Recurrent Glioblastoma | Phase 2 | Completed | David Peereboom | 41 | 2020-03-19 | 2024-08-28 |
| Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors Incomplete Freund's Adjuvant, Octreotide Acetate, Sargramostim - Lung Atypical Carcinoid Tumor, Lung Typical Carcinoid Tumor | Phase 1 | Completed | Roswell Park Cancer Institute | 19 | 2019-06-17 | 2026-02-06 |
| Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia. PD-L1, PD-L2 peptides with Montanide ISA51 - Chronic Lymphocytic Leukemia | Phase 2 | Completed | Lars Møller Pedersen | 19 | 2019-04-26 | 2022-02-21 |
| Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma 6MHP, Montanide ISA-51, polyICLC - Melanoma | Phase 1 / Phase 2 | Completed | Craig L Slingluff, Jr | 33 | 2018-11-13 | 2024-02-06 |
| Study of IFN-K in Dermatomyositis IFN-Kinoid, Placebo, ISA 51 - Dermatomyositis | Phase 2 | Withdrawn | Neovacs | 2017-05-03 | 2020-01-03 | |
| SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy Incomplete Freund's Adjuvant, Laboratory Biomarker Analysis, Lenalidomide - Partial Response of Multiple Myeloma or Plasma Cell Leukemia, Plasma Cell Myeloma | Phase 1 | Active not recruiting | Roswell Park Cancer Institute | 18 | 2017-04-13 | 2026-05-15 |
| Phase IIb Study of IFN-K in Systemic Lupus Erythematosus IFNα-Kinoid, Placebo, ISA 51 VG - Systemic Lupus Erythematosus | Phase 2 | Terminated | Neovacs | 185 | 2015-09-23 | 2020-04-09 |
| Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma 6MHP, Montanide ISA-51, polyICLC - Melanoma | Phase 1 / Phase 2 | Terminated | Craig L Slingluff, Jr | 48 | 2015-05-12 | 2023-10-30 |
| SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Laboratory Biomarker Analysis, Montanide ISA 51 VG, Sargramostim - Glioblastoma, Gliosarcoma | Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 66 | 2015-05-04 | 2026-10-22 |
| Clinical Efficacy of TNF-Kinoid in Patients With Rheumatoid Arthritis TNF-Kinoid, Placebo - Rheumatoid Arthritis | Phase 2 | Completed | Neovacs | 143 | 2013-09-01 | 2019-03-22 |
| Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery Montanide ISA 51 VG, MART-1 antigen, laboratory biomarker analysis - Recurrent Melanoma, Stage IIA Melanoma | Early Phase 1 | Completed | Mayo Clinic | 30 | 2012-10-01 | 2018-10-09 |
| A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS), MELITAC 12.1 + Montanide ISA-51 + polyICLC - Melanoma | Phase 1 | Completed | Craig L Slingluff, Jr | 53 | 2012-10-01 | 2016-08-12 |
| Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission basiliximab, WT1 126-134 peptide vaccine, Montanide ISA 51 VG - Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 1 | Completed | University of Chicago | 7 | 2011-12-05 | 2018-03-09 |
| A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH) Immucothel Alone (Part A), Immucothel+Montanide (Part A), Immucothel Alone or Immucothel+Montanide (Part B) - Autoimmune Disorders | Early Phase 1 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 19 | 2011-12-01 | 2016-04-12 |
| Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558 MART-1, NY-ESO-1, gp100:209-217(210M) - Melanoma (Skin) | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 127 | 2010-08-04 | 2023-01-18 |
Showing 20 of 54. Sign in to see all of them.
Melanoma (25) · Neoplasms (5) · Uveal Melanoma (5) · Breast Neoplasms (3) · Carcinoma, Renal Cell (3) · Skin Neoplasms (3) · Adenoma, Islet Cell (2) · Carcinoma, Non-Small-Cell Lung (2) · Eye Neoplasms (2) · Glioblastoma (2) · Lung Neoplasms (2) · Neoplasm Metastasis (2) · Prostatic Neoplasms (2) · Anemia, Refractory, with Excess of Blasts (1) · Arthritis, Rheumatoid (1)
National Cancer Institute (NCI) (16) · Roswell Park Cancer Institute (5) · Craig L Slingluff, Jr (3) · Neovacs (3) · University of Virginia (3) · Tokyo University (2) · University Hospital Tuebingen (2) · University of Southern California (2) · Centre Hospitalier Universitaire Vaudois (1) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1) · David Peereboom (1) · Eastern Cooperative Oncology Group (1) · Erasmus Medical Center (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Kinki University (1)
United States (38) · Belgium (4) · Japan (3) · Switzerland (3) · Colombia (2) · France (2) · Georgia (2) · Germany (2) · Italy (2) · Moldova (2) · Poland (2) · Russia (2) · Argentina (1) · Chile (1) · Croatia (1)
Craig L. Slingluff, MD (3) · Jeffrey Weber (3) · Arnulf Stenzl, Prof. (2) · Craig L Slingluff, MD (2) · Francesco M. Marincola (2) · Jasmeet Kaur, MD (2) · Steven A Rosenberg, M.D. (2) · Steven Rosenberg, M.D. (2) · Craig L Slingluff, Jr., MD (1) · Craig L. Slingluff, Jr., MD (1) · Daniel Speiser, MD (1) · David Peereboom, MD (1) · Douglas Schwartzentruber (1) · H. Richard Alexander (1)
PMID 11595689, PMID 12576434, PMID 18809608, PMID 19483644, PMID 21134985, PMID 21631324, PMID 22555974, PMID 23613128, PMID 23861247, PMID 24145345, PMID 24487961, PMID 25126421, PMID 28851380, PMID 29344432, PMID 31248461, PMID 31871140, PMID 32350119, PMID 33687069, PMID 36483037, PMID 36521103
2016 (1), 2018 (1), P30CA060553 (1), U10CA021115 (1), UG1CA242643 (1)